JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olivero, W. C.
Right arrow Articles by Lister, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olivero, W. C.
Right arrow Articles by Lister, J. R.

Journal of Neurology, Neurosurgery, and Psychiatry, 1995, Vol 58, 250-252


PAPERS

The use of PET in evaluating patients with primary brain tumours: is it useful?

WC Olivero, SC Dulebohn and JR Lister
Department of Neuroscience, University of Illinois College of Medicine at Peoria.

During an 18 month period 39 patients were evaluated with [18F] fluorodeoxyglucose-PET (FDG-PET) for primary brain tumours. These included patients with suspected newly diagnosed tumours and patients with known tumours who were being evaluated for possible recurrence or increasing tumour grade. Scans were performed on a 951-31 Siemen's PET scanner with 4 mm resolution. Scanning time was about 20 minutes per patient. All patients had undergone recent cerebral MRI. These patients were divided into two groups. In the first group (30) MRI and PET concurred on the diagnosis. The second group (nine) comprised those where the interpretation of MRI and PET was different or there was a question of the diagnosis on MRI. This group comprised three patients in whom MRI suggested recurrent tumour and PET inaccurately suggested radiation necrosis; two patients with newly diagnosed enhancing lesions on MRI in whom PET was useful in distinguishing strokes from tumour; two patients with prior gliomas with new enhancing isolated lesions on MRI in whom PET scan accurately depicted radiation necrosis; and two patients with newly diagnosed enhancing lesions on MRI in whom PET scan was helpful in distinguishing multiple sclerosis from tumour in one but not in the other. Therefore, of the 39 patients, PET was helpful in five in distinguishing tumour from other disease processes; but, in so far as influencing treatment, it seemed helpful in only two. Thus PET seems to be of limited value as an aid to evaluating and treating patients with suspected or known primary brain tumours.


© 1995 by Journal of Neurology, Neurosurgery, and Psychiatry



This article has been cited by other articles:


Home page
JNMHome page
Y. Terakawa, N. Tsuyuguchi, Y. Iwai, K. Yamanaka, S. Higashiyama, T. Takami, and K. Ohata
Diagnostic Accuracy of 11C-Methionine PET for Differentiation of Recurrent Brain Tumors from Radiation Necrosis After Radiotherapy
J. Nucl. Med., May 1, 2008; 49(5): 694 - 699.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. T. Wong and S. Brem
Taming Glioblastoma: Targeting Angiogenesis
J. Clin. Oncol., October 20, 2007; 25(30): 4705 - 4706.
[Full Text] [PDF]


Home page
JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. Chen
Clinical Applications of PET in Brain Tumors
J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
W. Chen, D. H.S. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy
18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy
J. Nucl. Med., June 1, 2006; 47(6): 904 - 911.
[Abstract] [Full Text] [PDF]


Home page
Mult SclerHome page
S. M Selkirk and J. Shi
Relapsing-remitting tumefactive multiple sclerosis
Multiple Sclerosis, December 1, 2005; 11(6): 731 - 734.
[Abstract] [PDF]


Home page
JNMHome page
W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H.S. Silverman
Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
J. Nucl. Med., June 1, 2005; 46(6): 945 - 952.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. D. Langleben and G. M. Segall
PET in Differentiation of Recurrent Brain Tumor from Radiation Injury
J. Nucl. Med., November 1, 2000; 41(11): 1861 - 1867.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
P. E. Ricci, A. Pitt, P. J. Keller, S. W. Coons, and J. E. Heiserman
Effect of Voxel Position on Single-Voxel MR Spectroscopy Findings
AJNR Am. J. Neuroradiol., February 1, 2000; 21(2): 367 - 374.
[Abstract] [Full Text]


Home page
RadiologyHome page
S. Cha, E. A. Knopp, G. Johnson, S. G. Wetzel, A. W. Litt, and D. Zagzag
Intracranial Mass Lesions: Dynamic Contrast-enhanced Susceptibility-weighted Echo-planar Perfusion MR Imaging
Radiology, April 1, 2002; 223(1): 11 - 29.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1995 by the BMJ Publishing Group Ltd.